Design, optimization, and evaluation for a long-time-released transdermal microneedle delivery system containing estradiol

Tang, XiaoFei; Qin, Huaiying; Zhang, XiaoYun; Yang, Haiyun; Yang, Jianhua; Chen, Ping; Jin, Yinli; Yang, Lu

doi:10.1007/s13346-023-01471-z

Cited by 2 publications

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To further demonstrate the versatility of this approach to generating microneedlebased biomedical microdevices, here we demonstrate their interfacing with phantom tissues mimicking normal healthy and cancerous tissues [32], and efficacy in delivering other bioactive molecules (specifically, estradiol [a hormone] [ [43][44][45], melatonin [a hormone] [46,47], and meropenem [a broad-spectrum antibiotic] [48,49]) in vitro.…”

Section: Introductionmentioning

confidence: 99%

Poly(2-Hydroxyethyl Methacrylate) Hydrogel-Based Microneedles for Bioactive Release

Sharma,

Abdelmohsen,

Kap

et al. 2024

Bioengineering

View full text Add to dashboard Cite

Microneedle arrays are minimally invasive devices that have been extensively investigated for the transdermal/intradermal delivery of drugs/bioactives. Here, we demonstrate the release of bioactive molecules (estradiol, melatonin and meropenem) from poly(2-hydroxyethyl methacrylate), pHEMA, hydrogel-based microneedle patches in vitro. The pHEMA hydrogel microneedles had mechanical properties that were sufficiently robust to penetrate soft tissues (exemplified here by phantom tissues). The bioactive release from the pHEMA hydrogel-based microneedles was fitted to various models (e.g., zero order, first order, second order). Such pHEMA microneedles have potential application in the transdermal delivery of bioactives (exemplified here by estradiol, melatonin and meropenem) for the treatment of various conditions.

show abstract

Section: Introductionmentioning

confidence: 99%

Poly(2-Hydroxyethyl Methacrylate) Hydrogel-Based Microneedles for Bioactive Release

Sharma,

Abdelmohsen,

Kap

et al. 2024

Bioengineering

View full text Add to dashboard Cite

show abstract

Nanomaterial-Enhanced Microneedles: Emerging Therapies for Diabetes and Obesity

Abbasi,

Boka,

DeLoit

2024

Pharmaceutics

View full text Add to dashboard Cite

Drug delivery systems (DDS) have improved therapeutic agent administration by enhancing efficacy and patient compliance while minimizing side effects. They enable targeted delivery, controlled release, and improved bioavailability. Transdermal drug delivery systems (TDDS) offer non-invasive medication administration and have evolved to include methods such as chemical enhancers, iontophoresis, microneedles (MN), and nanocarriers. MN technology provides innovative solutions for chronic metabolic diseases like diabetes and obesity using various MN types. For diabetes management, MNs enable continuous glucose monitoring, diabetic wound healing, and painless insulin delivery. For obesity treatment, MNs provide sustained transdermal delivery of anti-obesity drugs or nanoparticles (NPs). Hybrid systems integrating wearable sensors and smart materials enhance treatment effectiveness and patient management. Nanotechnology has advanced drug delivery by integrating nano-scaled materials like liposomes and polymeric NPs with MNs. In diabetes management, glucose-responsive NPs facilitate smart insulin delivery. At the same time, lipid nanocarriers in dissolving MNs enable extended release for obesity treatment, enhancing drug stability and absorption for improved metabolic disorder therapies. DDS for obesity and diabetes are advancing toward personalized treatments using smart MN enhanced with nanomaterials. These innovative approaches can enhance patient outcomes through precise drug administration and real-time monitoring. However, widespread implementation faces challenges in ensuring biocompatibility, improving technologies, scaling production, and obtaining regulatory approval. This review will present recent advances in developing and applying nanomaterial-enhanced MNs for diabetes and obesity management while also discussing the challenges, limitations, and future perspectives of these innovative DDS.

show abstract

Design, optimization, and evaluation for a long-time-released transdermal microneedle delivery system containing estradiol

Cited by 2 publications

References 41 publications

Poly(2-Hydroxyethyl Methacrylate) Hydrogel-Based Microneedles for Bioactive Release

Poly(2-Hydroxyethyl Methacrylate) Hydrogel-Based Microneedles for Bioactive Release

Nanomaterial-Enhanced Microneedles: Emerging Therapies for Diabetes and Obesity

Contact Info

Product

Resources

About